Dec 12 (Reuters) - Danish drugmaker Novo Nordisk
launched its blockbuster diabetes drug Ozempic in
India on Friday.
Ozempic, a once-weekly injectable approved by the U.S. Food
and Drug Administration in 2017 for type 2 diabetes, has become
a global bestseller and is widely used off-label for weight loss
due to its appetite-suppressing effects.